Teclison
Teclison Limited is dedicated to transforming cancer treatment by developing innovative therapies that induce tumor necrosis and enhance antitumor immunity. Their platform radically remodels the tumor immune microenvironment of solid cancers, aiming to improve the effectiveness of immunotherapies and achieve long-term remission for patients with metastatic solid tumor cancers.
Industries
biotechnology
Nr. of Employees
small (1-50)
Patents
Products
TATE platform therapy
A transarterial embolization therapy that induces complete tumor necrosis in intermediate-stage liver cancer patients, resulting in significantly improved survival compared to standard of care.
TATE platform therapy
A transarterial embolization therapy that induces complete tumor necrosis in intermediate-stage liver cancer patients, resulting in significantly improved survival compared to standard of care.
Services
Engagement and collaboration with external organizations for research, development, and investment related to oncology therapeutic programs.
Engagement and collaboration with external organizations for research, development, and investment related to oncology therapeutic programs.
Expertise Areas
- Immuno-oncology
- Tumor immune microenvironment modulation
- Combination therapy development with immune checkpoint inhibitors
- Liver-metastatic solid tumor therapeutics
Key Technologies
- Tumor immune microenvironment modulation
- Immuno-oncology therapeutics
- Combination therapy with immune checkpoint inhibitors
- Tumor necrosis induction mechanisms